Back to results
US 11,299,541 B2Granted
Biopharmaceutical compositions
AssigneeGlaxosmithkline Intellectual Property (No.2) Limited
InventorsMyrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
Claims19
A composition comprising:
- a) an anti-IL-5 antibody having a heavy chain amino acid sequence as shown in SEQ ID NO:
- 1 and a light chain amino acid sequence as shown in SEQ ID NO:
- 2, and
- b) acidic antibody variants of the anti-IL-5 antibody wherein ≤80% of antibodies in the composition are the acidic antibody variants, wherein the acidic antibody variants comprises:
- SEQ ID NO:
- 1, except that residue N386 of Seq ID NO:
- 1 is deamidated, or
- SEQ ID NO:
- 2, except that residue N31 of Seq ID NO:
- 2 is deamidated, or a combination thereof.
7 more elements
Dependencies are inferred from the claim text.